Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 18/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 16/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 16/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19840120 | 0.93 | OPRM1 (0.52) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL17279317 | 0.91 | OPRM1 (0.55) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL15848154 | 0.90 | OPRM1 (0.48) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL15848115 | 0.88 | OPRM1 (0.53) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL15847938 | 0.86 | OPRL1 (0.58) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL15861264 | 0.86 | OPRM1 (0.60) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL15861075 | 0.86 | OPRM1 (0.60) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL15861063 | 0.86 | OPRM1 (0.60) | OPRM1OPRL1OPRK1OPRD1 | |
| SCHEMBL15861077 | 0.84 | OPRM1 (0.47) | OPRM1OPRL1OPRK1 | |
| SCHEMBL15861064 | 0.84 | OPRM1 (0.47) | OPRM1OPRL1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2938341-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9884844-B2 | Heterocyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884844-B2 | Heterocyclic compounds and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-11-26 | — | — | US | disclosed |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-11-26 | — | — | US | disclosed |
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-11-26 | — | — | US | disclosed |
| EP-2938341-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2015-11-04 | — | — | EP | disclosed |
| WO-2014106238-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | FANG, QUN, KEVIN (US) | 2014-07-03 | — | — | WO | disclosed |
| WO-2014106238-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | FANG, QUN, KEVIN (US) | 2014-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | GRIN2C, COMT, NLN | OPRM1 259/4885OPRL1 771/4885OPRK1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.